The length of ICU stays and the need for endotracheal intubation in the LC group were significantly less than in the control group ( P 0.05, Table 1)
Semaglutide provides the core metabolic benefits: appetite suppression, improved insulin sensitivity, reduced glucagon secretion, and delayed gastric emptying
As only one patient with IIH-WOP was treated with a GLP-1-RA, this was insufficient to conduct subgroup analyses, so we could only perform sensitivity analyses removing IIH-WOP patients to exclude potential confounding effect on our results
Angiogenesis (VEGFR2)
+ BPC-157, TB-500, Semaglutide, Tirzepatide, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Retatrutide, Sermorelin, Tesamorelin, GHRP-2, GHRP-6, Hexarelin, and Melanotan II
Herrera, C